首页> 外文期刊>Reports of Biochemistry and Molecular Biology >Investigation of Aneusomy of Chromosome 21 in the Micronuclei of 13 Patients with Early Onset Alzheimer’s Disease Using Fluorescence in Situ Hybridization: A Pilot Study
【24h】

Investigation of Aneusomy of Chromosome 21 in the Micronuclei of 13 Patients with Early Onset Alzheimer’s Disease Using Fluorescence in Situ Hybridization: A Pilot Study

机译:荧光原位杂交用荧光研究13例患者染色体21例染色体21例染色体术语的研究:试验研究

获取原文
           

摘要

Background: Alzheimer’s disease is one of the most common neurodegenerative and dementia disorders in people between the ages of 30 and 65. When symptoms appear in this age group, the disease is referred to as early-onset Alzheimer’s disease (EOAD). Unfortunately, the symptoms are progressive and no current treatments are effective. Methods: In this research, 13 patients, aged 37 to 65 years with symptoms of early-onset Alzheimer’s disease, were studied. First, patient lymphocytes were isolated and cultured in RPMI 1640 medium using a special micronucleus (MN) culture method. Next, the lymphocytes were harvested and prepared on slides. The slides were then examined by fluorescent microscopy using a unique FISH protocol specific for MNs. The patients were divided into groups aged 30-39, 40-49, and 50-65. Results:We found that 19.76% of the MNs from our EOAD patients originated in chromosome 21. Micronuclei originated in chromosome 21 in 21.20 and 16.52% of patients without and with family histories of Alzheimer’s, respectively. This difference was not significant. Also, the percentage of micronuclei originating in chromosome 21 was not dependent on the patient age at the time of the study, or symptom onset age or duration. Conclusions: This study shows that the rate of micronuclei with the origin of chromosome 21 is high in these patients. However, the micronucleus increased has no significant relationship with age and duration of disease or family history of it.
机译:背景:阿尔茨海默病是在30%和65岁之间的人们中最常见的神经退行和痴呆症之一。当症状出现在该年龄组中时,该疾病被称为早期发作的阿尔茨海默病(EAID)。不幸的是,症状是进步的,并且没有目前的治疗是有效的。方法:在本研究中,研究了13名患者,37至65岁,患有早期阿尔茨海默病的症状。首先,使用特殊的微核(Mn)培养方法在RPMI 1640培养基中分离和培养患者淋巴细胞。接下来,收获淋巴细胞并在载玻片上制备。然后使用针对MNS特异的独特的鱼协议,通过荧光显微镜检查载玻片。将患者分为30-39,40-49和50-65岁的组。结果:我们发现,来自我们的EAD患者的19.76%的MNS起源于21例染色体。微核在21.20和16.52%的患者中起源于21.20和16.52%的患者,分别与阿尔茨海默家族历史。这种差异并不重要。此外,染色体21中的微核的百分比不依赖于研究时的患者年龄,或症状发作年龄或持续时间。结论:本研究表明,在这些患者中,染色体21起源的微核率高。然而,微核增加与疾病或疾病的年龄和持续时间没有显着关系。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号